Indoco Remedies Limited

INDOCO

INE873D01024

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 07:43:48 2024-05-02 am EDT			5-day change	1st Jan Change
331.4 ^INR	+1.36%		+0.59%	-16.14%

Mar. 29	Indoco Remedies Limited Announces Cessation of Divakar M. Gavaskar and Rajiv P. Kakodkar as Independent Directors, Effective Mach 31, 2024	CI
Mar. 26	Indoco Remedies Arm Begins Commercial Production from New Manufacturing Unit	MT

Indoco Remedies Limited Announces That on July 29, 2023, Fire Occurred At Warehouse and Information Technology Office

July 29, 2023 at 01:26 pm EDT

Indoco Remedies Limited announced that on July 29, 2023 at around 12.25 a.m. (IST), fire occurred at warehouse and information technology (IT) office situated in the premises of unit located at B- 20 MIDC, Waluj, Aurangabad, Maharashtra- 431133. The fire was controlled, but production operation of the said Plant is temporarily disrupted. There are no human injuries or casualties reported.

Adequate steps are being undertaken to restore the operation of the Plant. The Company is in the process of ascertaining the cause of the fire and the actual loss caused by it.

Latest news about Indoco Remedies Limited

Indoco Remedies Limited Announces Cessation of Divakar M. Gavaskar and Rajiv P. Kakodkar as Independent Directors, Effective Mach 31, 2024	Mar. 29	CI
Indoco Remedies Arm Begins Commercial Production from New Manufacturing Unit	Mar. 25	MT
Indoco Remedies to Buy Land in Mumbai for Expansion	Mar. 12	MT
Indoco Remedies Arm Begins Commercial Production at New Oral Care Unit	Mar. 04	MT
Transcript : Indoco Remedies Limited, Q3 2024 Earnings Call, Jan 23, 2024	Jan. 23
Indoco Remedies' Consolidated Profit Slumps in Fiscal Q3; Shares Drop 6%	Jan. 23	MT
Indoco Remedies Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Jan. 23	CI
Indoco Remedies Gets Establishment Inspection Report from US FDA after Goa Unit Inspection	Jan. 18	MT
Indoco Remedies Gets Tentative US FDA Nod for Generic Diabetes Drug	Dec. 06	MT
Indoco Remedies Receives Tentative ANDA Approval from USFDA for Canagliflozin Tablets	Dec. 06	CI
Indoco Remedies' Solid Oral Formulation Plant in Goa, India, Gets Four Observations from US FDA	23-10-19	MT
Transcript : Indoco Remedies Limited, Q2 2024 Earnings Call, Oct 19, 2023	23-10-19
Indoco Remedies Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	23-10-19	CI
Indoco Remedies Limited Declares Final Dividend for the Financial Year Ended March 31, 2023	23-09-26	CI
Indoco Remedies Limited Announces Resignation of Sachin Ghosalkar as the Sr. Vice-President	23-08-31	CI
Indoco Remedies Secures INR30 Million Insurance Money for Claim Against Fire Incident	23-08-28	MT
Indoco Remedies Limited Resumes Production Operations at Warehouse and Information Technology Office	23-08-04	CI
Indoco Remedies Limited Announces That on July 29, 2023, Fire Occurred At Warehouse and Information Technology Office	23-07-29	CI
Indoco Remedies' Baddi Facility Gets EU GMP Certification from Malta Health Authority	23-07-26	MT
Transcript : Indoco Remedies Limited, Q1 2024 Earnings Call, Jul 25, 2023	23-07-25
Indoco Remedies Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-07-25	CI
Indoco Remedies Gets German Health Authority's GMP Certification for Oral Dosage Facility	23-07-11	MT
German Health Authority Clears Indoco Remedies' Oral Solid Dosage Plant in India	23-06-09	MT
Indoco Remedies to Acquire Majority Stake in Florida Pharmaceutical Products Parent	23-06-05	MT
Indoco Remedies Limited agreed to acquire a 85% stake in Florida Pharmaceutical Products, Inc. from Contract Pharmacal Corp. for $4 million.	23-06-05	CI

Chart Indoco Remedies Limited

Duration

Period

More charts

Company Profile

Indoco Remedies Limited is an India-based manufacturer of pharmaceutical products. The Company is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs). The Company offers medicines in multiple therapeutic categories, such as diabetology, respiratory, stomatology, women's health, nutritional products, gastroenterology, cardiology, metabolic disorders and primary care medicine. Its products/brands include Cyclopam, Sensodent-K, Karvol Plus, Sensoform, Cital UTI, Kidodent, Rexidin M, Lignox A, Dentogel, Aloja, Homide, Renolen, Noxa, Dexoren - S, Aloja M, ATM, Febrex Plus, Sensodent-KF, SM Fibro, MCBM 69, Cal Aid, Snowdent, Dropizin, Zincoren, Coloferrin, Bfloren, RR Sensoform Dental, Mofloren-D, and Tuspel among others. The Company caters to both domestic and international markets. Its subsidiaries include Xtend Industrial Designers and Engineers Pvt Ltd, Indoco Remedies Czech sro, and Indoco Remedies UK Limited.

Sector

Pharmaceuticals

Calendar

2024-05-28 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Indoco Remedies Limited

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

331.4 INR

Average target price

395.2 INR

Spread / Average Target

+19.25%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
INDOCO REMEDIES LIMITED	-16.14%	361M
ELI LILLY AND COMPANY	+29.68%	699B
NOVO NORDISK A/S	+25.07%	571B
JOHNSON & JOHNSON	-4.35%	364B
MERCK & CO., INC.	+17.65%	326B
ABBVIE INC.	+3.77%	286B
ASTRAZENECA PLC	+14.68%	236B
NOVARTIS AG	+4.71%	198B
ROCHE HOLDING AG	-12.43%	194B
PFIZER, INC.	-3.79%	154B

Other Pharmaceuticals